The authors conclude that “knowledgeable prescribing of medications” as adjunctive components of a holistic approach to weight loss can “aid in the prevention and management of obesity and thus improve health.”


Continue Reading

  1. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 Jan 15:jc20143415. [Epub ahead of print]
  2. American Medical Association. Policy H-440.842. Recognition of Obesity as a Disease; 2013.
  3. Allison DB, Downey M, Atkinson RL, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity. 2008;16:1161–1177.
  4. Wadden TA, Berkowitz RI, Sarwer DB, et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 2001;161:218–227.
  5. Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293–316.
  6. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111–2120.
  7. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20:1426–1436.
  8. Qsymia (phentermine and topiramate extended-release) [prescribing information]. Mountain View, CA: Vivus Inc. pdf/prescribing-information.pdf. Accessed July 2, 2014.
  9. Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc.
  10. Accessed July 2, 2014.

  11. Alli (orlistat) [label]. Moon Township, PA: GlaxoSmithKline.
  12. Approved February 7, 2007. Accessed July 2, 2014.

  13. Belviq (lorcaserin) [prescribing information]. Zofingen, Switzerland: Arena Pharmaceuticals GmbH.
  14. Accessed July 2, 2014.

  15. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 suppl 2):S102–S138.
  16. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.
  17. Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. Int J Obes Relat Metab Disord. 2001;25;741–747.
  18. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167–172.
  19. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;10:CD006423.
  20. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):323–329.
  21. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) [Errata (2012) 36:890 and (2013) 37:322]. 2012;36:843–854.
  22. Feng P, Yu M, Chen LM, et al. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacol Sin. 2015 Jan 26. [Epub ahead of print]
  23. Iglesias P, Civantos S, Vega B. Clinical Effectiveness of Exenatide in Diabetic Patients Waiting for Bariatric Surgery. Obes Surg. 2015 Jan 15. [Epub ahead of print]
  24. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005;48(5):838–848.
  25. Smith SR, Blundell JE, Burns C, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab. 2007;293(2):e620–e627.
  26. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab. 2007;9:386–393.
  27. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92:2977–2983.
  28. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103–112.
  29. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747.
  30. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592.
  31. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
  32. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71:1259–1272.
  33. Domecq JP, Prutsky G, Leppin A, et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:363–370.
  34. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
  35. Simpson GM, Glick ID, Weiden PJ et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–1847.
  36. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;4:CD006627.
  37. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21:517–535.
  38. Ben-Menachem E. Weight issues for people with epilepsy–a review. Epilepsia. 2007;48(suppl 9):42–45.
  39. Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;1:CD003987.
  40. Stricker RB, Goldberg B. Weight gain associated with protease inhibitor therapy in HIV-infected patients. Res Virol. 1998;149:123–126.
  41. Da Silva JA, Jacobs JW, Bijlsma JW. Revisiting the toxicity of low-dose glucocorticoids: risks and fears. Ann NY Acad Sci. 2006;1069:275–288.
  42. Ratliff JC, Barber JA, Palmese LB, et al. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring). 2010;18:2398–2400.